Want to see VBIO full AI Analyst Report?
Top Page
Valion Bio
(NASDAQ:VBIO)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.89
▼(-35.36% Downside)
Action:Reiterated
Date:05/02/26
The score is primarily constrained by very weak financial performance (shrinking revenue, persistent losses, negative cash flow, and significant balance-sheet erosion). Technicals are mixed but generally pressured by longer-term downtrends, while valuation is hard to support due to negative earnings and no dividend data.
Positive Factors
Low Leverage
Reported zero debt in 2024–2025 materially reduces bankruptcy and interest-service risk, preserving balance-sheet flexibility. Over a 2–6 month horizon this low leverage supports survival through weak operations and provides optionality to raise structured financing or equity on more favorable terms if needed.
Negative Factors
Declining Revenue
A multi-year revenue decline signifies weakening demand and loss of scale, which undermines gross margin recovery and operating leverage. Over 2–6 months this constrains resource allocation for marketing, R&D, and distribution, making it harder to rebuild market position without material new investment or a strategic commercial shift.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Reported zero debt in 2024–2025 materially reduces bankruptcy and interest-service risk, preserving balance-sheet flexibility. Over a 2–6 month horizon this low leverage supports survival through weak operations and provides optionality to raise structured financing or equity on more favorable terms if needed.
Read all positive factors
Valion Bio (VBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.29M
Dividend YieldN/A
Average Volume (3M)99.84K
Price to Earnings (P/E)―
Beta (1Y)1.48
Revenue Growth-49.63%
EPS Growth82.22%
CountryUS
Employees52
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding4,151,259
10 Day Avg. Volume91,463
30 Day Avg. Volume99,839
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)17.36
Price to Sales (P/S)197.61
P/FCF Ratio-41.06
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Valion Bio Business Overview & Revenue Model
Company Description
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat...
How the Company Makes Money
Tivic Health Systems primarily makes money by selling its ClearUP device and related accessories to customers, with revenue recognized from product sales through direct-to-consumer channels and/or retail or distribution partners. To the extent the...
Valion Bio Earnings Call Summary
Earnings Call Date:Nov 14, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Neutral
Tivic Health demonstrated substantial progress in its strategic transformation and development of Entolimod, improving its financial position despite experiencing increased net loss and manufacturing delays.Positive Updates
Strategic Transformation
Tivic Health expanded from bioelectronics to biologic pharmaceuticals, focusing on immune system-related treatments.
Negative Updates
Increased Net Loss
Net loss for Q3 2025 was $2.6 million compared to $1.4 million in Q3 2024.
Read all updates
Q3-2025 Updates
Positive
Negative
Strategic Transformation
Tivic Health expanded from bioelectronics to biologic pharmaceuticals, focusing on immune system-related treatments.
Read all positive updates
Company Guidance
During the third quarter of 2025, Tivic Health Systems reported significant progress in its strategic transformation towards the biopharmaceutical market, having licensed entolimod and related assets to pivot from bioelectronics to biologic pharmaceuticals. The company is focusing on entolimod as a military countermeasure for acute radiation syndrome (ARS) and has moved forward with transferring two INDs related to ARS and advanced cancer. Financially, Tivic saw revenue net of returns at $140,000 for the quarter, an increase from $126,000 in the previous year, although nine-month revenue decreased to $302,000 from $600,000 due to reduced advertising spend. The cost of sales rose to $291,000, influenced by a $230,000 inventory reserve, while gross margins excluding this reserve improved to 42% from 35%. Operating expenses increased to $2,300,000 from $1,500,000 due to heightened R&D investments and corporate costs. The net loss widened to $2,600,000 from $1,400,000, and cash reserves grew to $3,500,000, supported by additional financing tranches totaling $3,800,000 during the quarter.Valion Bio Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
25
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2022 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.69M | 0.00 | 0.00 | 0.00 | 102.42K | 163.36K |
| Gross Profit | -191.73K | 0.00 | 0.00 | 0.00 | 24.48K | 55.10K |
| EBITDA | 949.96K | -880.85K | -3.69M | -4.43M | -4.31M | -5.22M |
| Net Income | -2.47M | -880.85K | -4.37M | -20.14M | -4.31M | -5.22M |
Balance Sheet | ||||||
| Total Assets | 119.68M | 896.83K | 2.57M | 6.08M | 675.79K | 1.18M |
| Cash, Cash Equivalents and Short-Term Investments | 1.28M | 884.14K | 2.39M | 5.98M | 656.29K | 1.15M |
| Total Debt | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 85.86M | 33.44K | 1.28M | 1.05M | 353.52K | 800.65K |
| Stockholders Equity | 20.38M | 863.39K | 1.28M | 5.02M | 322.27K | 374.37K |
Cash Flow | ||||||
| Free Cash Flow | -17.23K | -1.61M | -3.59M | -3.67M | -2.89M | -1.38M |
| Operating Cash Flow | -17.23K | -1.61M | -3.59M | -3.67M | -2.89M | -1.38M |
| Investing Cash Flow | -328.87K | 0.00 | 0.00 | 141.54K | 0.00 | 0.00 |
| Financing Cash Flow | 463.86K | 96.99K | 0.00 | 8.85M | 2.39M | 2.44M |
Valion Bio Technical Analysis
Negative
1.38
Price Trends
0.56
Negative
0.78
Negative
1.22
Negative
Market Momentum
-0.09
Positive
26.89
Positive
10.89
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VBIO, the sentiment is Negative. The current price of 1.38 is above the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.56, and above the 200-day MA of 1.22, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 26.89 is Positive, neither overbought nor oversold. The STOCH value of 10.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VBIO.
Valion Bio Risk Analysis
Valion Bio disclosed 59 risk factors in its most recent earnings report. Valion Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Valion Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $1.29M | -10.33 | -18.83% | ― | -49.63% | 82.22% | |
44 Neutral | $299.02M | -1.44 | -12.66% | ― | 100.82% | 42.21% | |
44 Neutral | $889.86K | -0.05 | -144.27% | ― | ― | 98.81% | |
43 Neutral | $633.87K | ― | -9999.00% | ― | -0.20% | 91.63% | |
41 Neutral | $1.75M | -0.04 | -137.73% | ― | ― | 81.30% |
* Healthcare Sector Average
VBIO
Valion Bio
0.31
-2.90
-90.34%
NUWE
Nuwellis
1.74
-229.61
-99.25%
AEMD
Aethlon Medical
0.66
-11.44
-94.53%
BBLG
Bone Biologics
0.85
-1.90
-69.16%
MOVE
Movano
10.82
6.23
135.78%
BJDX
Bluejay Diagnostics
0.86
-5.12
-85.62%
Valion Bio Corporate Events
Business Operations and StrategyProduct-Related Announcements
Valion Bio advances Entolimod platform and manufacturing scale-up
Positive
Jul 15, 2026
On July 14, 2026, Valion Bio reported a series of developments that mark its evolution from a single-product developer into a broader platform company. The update highlighted the Entolimod program’s positioning across government radiation pr...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Valion Bio Completes New Preferred Stock Financing Round
Positive
Jun 18, 2026
On June 17, 2026, Valion Bio, Inc. issued 250 shares of its Series B Non-Voting Convertible Preferred Stock at $1,000 per share and a warrant to purchase 156,026 shares of common stock at an exercise price of $0.616280 per share to 3i, LP, for tot...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingShareholder Meetings
Valion Bio Shareholders Approve Director, Auditor and Equity Plan
Positive
Jun 3, 2026
On May 28, 2026, Valion Bio held its annual meeting virtually, with 50% of the 3,139,095 outstanding common shares represented, establishing a quorum while preferred shareholders remained non-voting on the matters presented. Stockholders elected C...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Valion Bio Reports Q1 Results, Advances Entolimod Platform
Negative
May 14, 2026
On May 14, 2026, Valion Bio reported its first-quarter 2026 results, marking its first full reporting period under the new corporate identity and post-divestiture of its legacy consumer bioelectronics business. During the quarter ended March 31, 2...
Business Operations and StrategyExecutive/Board Changes
Valion Bio Appoints Melinda Lackey as General Counsel
Positive
May 4, 2026
On May 4, 2026, Valion Bio appointed biopharmaceutical attorney Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs, following the execution of her employment agreement on May 1, 2026. Lackey, who brings nearly two decades...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.